Find out why the modular approach to ligand design has quickly gained acceptance in the world of rational drug design. Here, experts from leading pharmaceutical companies discuss latest technologies and strategies for fragment-based approaches in the screening and design of pharmaceutically active compounds. Includes recent case studies from the pharmaceutical industry.
Wolfgang Jahnke studied Chemistry at the University of Tubingen (Germany) and obtained a Ph.D. degree from the University of M? with Horst Kessler in 1994. He then joined the pharmaceutical industry and is currently head of a drug discovery group at Novartis Pharma AG in Basel (Switzerland). His main expertise is on the application of NMR spectroscopy for drug discovery. In recent years, this has included the development of novel methods for fragment-based ligand design and the characterization of protein-ligand interactions.